Company: BLRX
Filing Date: 2025-07-25
Form Type: 424B5
Source: 0001178913-25-002463
Chunk: 1

Company: BioLineRx Ltd.
Filing Date: 2025-07-25
Form: 424B5
Chunk 1
---
 the closing price of our ADSs on the Nasdaq was $4.51 per ADS. Our ordinary
      shares also trade on the Tel Aviv Stock Exchange, or TASE, under the symbol “BLRX”. On July 24, 2025, the last reported sale price of our ordinary shares on the TASE was NIS 0.025 or $0.0075 per share (based on the exchange rate reported by the Bank
      of Israel on the same day).

The aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates as of the date of this prospectus supplement, based on the closing price of
      the ADSs on the Nasdaq on June 9, 2025, as calculated in accordance with General Instruction I.B.5. of Form F-3, was approximately $24.2 million. Pursuant to General Instruction I.B.5 of Form F-3, in no event will we sell securities in a primary
      offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000. During the prior 12 calendar month period that ends on, and includes, the date of this prospectus
      supplement (excluding this offering), we sold securities with an aggregate market value of $3,194,586 pursuant to General Instruction I.B.5 of Form F-3. In the event that we may sell additional amounts under the Sales Agreement, we will file another
      prospectus supplement prior to making such additional sales.

Investing in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well as the
        information incorporated herein and therein by reference carefully before you make your investment decision. See “Risk Factors” beginning on page S-5 of the ATM Prospectus and on page S-1 of the accompanying prospectus, and the risk factors
        described in other documents incorporated by reference therein, to read about the factors you should consider before investing in our securities.

Neither the U.S. Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or
        disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.**

#### H.C. Wainwright & Co.
<div align='center'>**The date of this prospectus supplement is July